

UNIVERSITY of NORTH TEXAS HEALTH SCIENCE CENTER  
OFFICE of RESEARCH COMPLIANCE  
INSTITUTIONAL REVIEW BOARD

SERIOUS  
ADVERSE EVENT  
(SAE) REPORT

ON-SITE  
(UNTHSC)

The FDA defines a serious adverse event as any experience that suggests a significant hazard, contraindication, side effect or precaution. With respect to human clinical experience, a serious adverse drug or device event includes any experience that is fatal or life-threatening, is permanently disabling, requires or prolongs inpatient hospitalization, results in a congenital anomaly/birth defect, pregnancy\*, or may be classified as an important medical event (requiring medical or surgical intervention). This form must be completed and forwarded, along with supporting documentation, within 10 working days of the incident. Please use lay terminology when possible and avoid the use of abbreviations.

IRB Project # \_\_\_\_\_ Contact Person and Phone # (if different from P.I.) \_\_\_\_\_

Principal Investigator: \_\_\_\_\_

Project Title: \_\_\_\_\_

Sponsor Protocol # \_\_\_\_\_ Subject's Initials: \_\_\_\_\_ Sex M  F  Age: \_\_\_\_\_

Date and Time of Adverse Event \_\_\_\_\_ Date Study Staff Informed of Event \_\_\_\_\_

Nature of Problem: \_\_\_\_\_

**ATTACH A DETAILED DESCRIPTION OF THE ADVERSE EVENT, TREATMENT AND LONG-TERM PROGNOSIS.**

Initial  Follow-Up  Will the subject remain in study? Yes  No

Was the event associated with or the cause of any of the following?

- Death
- Life-Threatening Situation
- Hospitalization or Prolonged Hospitalization
- Severe or Permanent Disability
- No Congenital Anomaly/Birth Defect
- Pregnancy \*
- Other (Important Medical Event)

In the **Principal Investigator's** opinion, was the adverse event related to the protocol?

- Definitely Yes
- Probably Yes
- Possibly
- Probably No
- Definitely No
- Unknown

*\*Pregnancy does NOT have to be reported if the subject is receiving follow-up only, and conception occurred outside of the time period that the study protocol requires contraception (e.g. contraception is required for 6 months after the last dose of the study drug)*

In the case of an investigational drug or device, have you reported the event to the sponsor?  Yes  No

If yes, **please attach a copy of the information sent to the study sponsor.**

Has this type of adverse event been reported before?  Yes  No

Is this type of event likely to occur again?  Yes  No  Possibly  Unknown

Action to be taken as a result of this report: (check all that apply)

- None (causality assessed as NOT related or follow-up report with NO change in causality or event terms)
- "Information on this type of event already contained in consent form
- First report of event assessed as related
- "Will monitor for trends
- Consent Form to be revised (**Attach the revised consent form with changes highlighted and a "clean" copy**)
- "Other (please specify): \_\_\_\_\_

The undersigned agrees that the submitted information is accurate and, to the best of their knowledge, complete:

Receipt and review of this serious adverse event report is acknowledged:

\_\_\_\_\_  
Signature - Principal Investigator      Date

\_\_\_\_\_  
Signature - IRB Chairman      Date